Financing channel feed

Ved­aBio launch­es with $40M+ in ini­tial fund­ing for CRISPR-based mol­e­c­u­lar de­tec­tion tech­nol­o­gy

Last year
Startups
Diagnostics

Atom Bio­science rais­es $83M in Se­ries D for URAT1 in­hibitor in chron­ic gout treat­ment

Last year
R&D

Bellerophon's board ap­proves liq­ui­da­tion plan, leaves Nas­daq af­ter lay­offs and tri­al fail­ures

Last year
People

BioN­Tech ex­pects up to $950M in Covid vac­cine write-offs af­ter Pfiz­er low­ers ex­pec­ta­tions

Last year
Coronavirus

HHS se­lects in­tranasal vac­cine can­di­dates for Project NextGen, doles out $500M in funds

Last year

#Eu­ro­Bio23: The down­turn, tak­ing risks and the ‘biotech mafia’

Last year
People
Deals

As­tria nabs pre­clin­i­cal OX40 atopic der­mati­tis drug for $15M up­front, prices $64M of­fer­ing

Last year
Deals

Ex­clu­sive: Liq­uid-biop­sy start­up clos­es $17M to fund ovar­i­an can­cer di­ag­nos­tic test

Last year
Diagnostics

Phar­ma-backed Min­er­vaX rais­es €54M as it aims to move its group B Strep­to­coc­cus vac­cine in­to PhI­II

Last year

Agomab draws $100M for fi­bro­sis pipeline, adding to drum­beat of nine-fig­ure Se­ries C rounds

Last year
Startups

Ex­clu­sive: An­dreessen Horowitz-backed start­up is us­ing AI to de­sign lipid nanopar­ti­cles that go be­yond the liv­er

Last year

Re­turn of the megaround: Main Street Health rais­es $315M for val­ue-based care: #HLTH23

Last year
Health Tech

No­var­tis, Bris­tol My­ers back $61M Se­ries A raise for de­men­tia biotech As­tro­nauTx

Last year
Startups

An­timi­cro­bial re­sis­tance biotech se­cures $37M with ex-Cure­Vac CEO Franz-Wern­er Haas at the helm

Last year

BMS-backed liq­uid biop­sy biotech Pre­cede Bio­sciences de­buts to en­hance pre­ci­sion med­i­cine ap­proach­es

Last year
Startups
Diagnostics

AI-dri­ven biotech Iambic snags $100M to en­ter the clin­ic next year in HER2 field

Last year
Startups
AI

Ex­clu­sive: Di­men­sion leads $40M round for lab au­toma­tion com­pa­ny Au­toma­ta Tech­nolo­gies

Last year

Lex­eo Ther­a­peu­tics and Abi­vax seek Nas­daq list­ings in shrink­ing pre-Thanks­giv­ing win­dow for biotech IPOs

Last year

Madri­gal rais­es $500M for NASH drug launch, dis­clos­es cy­ber­at­tack

Last year

With its ex-No­var­tis can­cer drug near the fin­ish line, Ad­lai Nortye rais­es $97.5M in Nas­daq de­but

Last year

Scoop: Led by for­mer Trump of­fi­cial, Al­te­sa Bio­Sciences rais­es $35M for an­tivi­rals, re­cruits Mon­cef Slaoui to board

Last year
People

Stephen Hahn’s liq­uid biop­sy com­pa­ny Har­bin­ger Health rais­es $140M Se­ries B to launch first can­cer tests by 2025

Last year
Diagnostics

Chica­go AI drug dis­cov­ery shop Evozyne nabs $81M in bid to make new pro­teins

Last year

Ex­clu­sive: CellFE rais­es $22M Se­ries A to ad­vance a new cell ther­a­py man­u­fac­tur­ing idea

Last year
Cell/Gene Tx
Manufacturing
First page Previous page 26272829303132 Next page Last page
A service from the Financial Times